David Endicott Joins Orexigen Therapeutics Board of Directors

        David Endicott Joins Orexigen Therapeutics Board of Directors

PR Newswire

SAN DIEGO, Nov. 30, 2012

SAN DIEGO, Nov. 30, 2012 /PRNewswire/ -- Orexigen^® Therapeutics, Inc.
(Nasdaq: OREX), a biopharmaceutical company focused on the treatment of
obesity, today announced the appointment of David Endicott to its board of
directors.

Mr. Endicott brings over 25 years ofpharmaceutical and healthcare experience
serving leadership roles in the U.S. and internationally at Allergan, Inc. He
currently serves asPresident of Allergan Medical, Asia Pacific and Latin
America.Prior to this heserved in roles as President, Allergan Medical and
President of Europe, Middle East and Africa. Mr. Endicott hasled Allergan's
U.S. Specialty Pharmaceuticals business, and established Allergan's Managed
Markets group in additiontoother leadership rolessince joining Allergan in
1986.

"During the course of his successful career at Allergan, David has managed the
international expansion of Allergan's businesses as well as important
divisions such as Managed Markets," said Michael Narachi, Orexigen's chief
executive officer. "We look forward to benefiting from his advice and
leadership experience in the coming years as we look to the possible approval
and commercial launch of Contrave^® in the United States and globally."

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave, which
has completed Phase III clinical trials and for which a New Drug Application
has been submitted and reviewed by the FDA. The Company has also reached
agreement with the FDA on a Special Protocol Assessment (SPA) for the Light
Study, the Contrave cardiovascular outcomes trial. The Company's other product
candidate, Empatic™, has completed Phase II clinical trials. Further
information about the Company can be found at www.orexigen.com.

Forward-Looking Statements
Orexigen cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements. Words
such as "believes," "anticipates," "plans," "expects," "indicates," "will,"
"should," "intends," "potential," "suggests," "assuming," "designed" and
similar expressions are intended to identify forward-looking statements. These
statements are based on the Company's current beliefs and expectations. These
forward-looking statements include statements regarding the the potential for
and timing of approval for Contrave globally.. The inclusion of
forward-looking statements should not be regarded as a representation by
Orexigen that any of its plans will be achieved. Actual results may differ
from those set forth in this release due to the risk and uncertainties
inherent in the Orexigen business, including, without limitation: Orexigen's
ability to conduct the Light Study and the progress and timing thereof;
Orexigen's ability to demonstrate in the Light Study that the risk of MACE in
overweight and obese subjects treated with Contrave does not adversely affect
the product candidate's benefit-risk profile; the potential that earlier
clinical trials may not be predictive of future results in the Light Study or
Phase III trials for Empatic; the Special Protocol Assessment (SPA) is not
binding on the FDA if public health concerns unrecognized at the time the SPA
agreement was entered into become evident, other new scientific concerns
regarding product safety or efficacy arise, or if Orexigen fails to comply
with the agreed upon trial protocol; the potential for the FDA or other
equivalent ex-US regulatory agency to not approve Contrave; the potential for
early termination of the collaboration agreement between Orexigen and Takeda;
the costs and time required to complete additional clinical, non-clinical or
other requirements prior to any resubmission of an NDA for Contrave; the
therapeutic and commercial value of Contrave; Orexigen's ability to maintain
sufficient capital; and other risks described in the Company's filings with
the Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof, and Orexigen undertakes no obligation to revise or update this news
release to reflect events or circumstances after the date hereof. Further
information regarding these and other risks is included under the heading
"Risk Factors" in Orexigen's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission November 9, 2012 and which is available
from the SEC's website (www.sec.gov) and on Orexigen's website
(www.orexigen.com) under the heading "Investor Relations." All forward-looking
statements are qualified in their entirety by this cautionary statement. This
caution is made under the safe harbor provisions of Section 21E of the Private
Securities Litigation Reform Act of 1995.

Orexigen Contact:                                     Media Contact:
McDavid Stilwell                                      Denise Powell
VP, Corporate Communications and Business Development WCG
(858) 875-8629                                        (510) 703-9491

SOURCE Orexigen Therapeutics, Inc.

Website: http://www.orexigen.com
 
Press spacebar to pause and continue. Press esc to stop.